Top Markets
Coin of the day
AbbVie Inc. AbbVie Inc.

AbbVie Inc.

ABBV
Clasificación en acciones #27
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery,... AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
Precio por acción
$265.95
Capitalización bursátil
$469.88B
Cambio (1 día)
0.34%
Cambio (1 año)
19.48%
País
US
Comercio AbbVie Inc. (ABBV)

Categoría

Ratio P/E de AbbVie Inc. (ABBV)
Ratio P/E al September 2026 TTM: 73.73
Según los últimos informes financieros y el precio de las acciones de AbbVie Inc., el P/E actual (TTM) de la empresa es 73.73. Al final de 2024, la empresa tenía un P/E de 73.48.
Historial del ratio P/E de AbbVie Inc. desde 2009 hasta 2026
Relación P/E al final de cada año
Año Ratio P/E Cambiar
2026 (TTM) 73.73 -23.85%
2025 96.82 31.76%
2024 73.48 30.42%
2023 56.34 132.99%
2022 24.18 16.46%
2021 20.76 -46.34%
2020 38.70 132.60%
2019 16.64 -33.40%
2018 24.98 -14.08%
2017 29.07 70.40%
2016 17.06 -8.83%
2015 18.71 -68.19%
2014 58.84 189.43%
2013 20.33 99.06%
2012 10.21 -38.01%
2011 16.47 21.70%
2010 13.54 10.97%
2009 12.20 0.00%
Relación P/E para empresas similares o competidores
Empresa P/E Ratio Diferencia del P/E Ratio País
38.12 -48.30%
US
30.79 -58.24%
US
22.25 -69.82%
CH
114.95 55.91%
US
22.23 -69.84%
CH
¿Cómo leer un P/E ratio?

El ratio Precio/Beneficio (P/E Ratio) mide la relación entre el precio de las acciones de una empresa y sus beneficios por acción.
Un P/E bajo pero positivo indica una empresa con altos beneficios en relación a su valoración actual y que podría estar infravalorada. Una empresa con un P/E negativo alto (cerca de 0) indica fuertes pérdidas en comparación con su valoración.

Las empresas con un P/E superior a 30 o negativo suelen considerarse "acciones de crecimiento", lo que significa que los inversores esperan que crezca o se vuelva rentable en el futuro.

Las empresas con un P/E positivo inferior a 10 suelen considerarse "acciones de valor", lo que significa que ya son muy rentables y no se espera un fuerte crecimiento.